Trials / Completed
CompletedNCT03100630
Compare Bioavailability of RO7239361 After Subcutaneous Injection
An Open-label, Randomized, Parallel-group, Single Dose Study to Compare the Bioavailability of Subcutaneous Injections in the Arm, Thigh, and Abdomen and to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of RO7239361 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 99 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Randomized study in healthy men and women. Assess the similarity of RO7239361 when injected into the arm, thigh, or the stomach. Collect data on safety of RO7239361.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RO7239361 | Specified dose on specified days |
Timeline
- Start date
- 2017-05-09
- Primary completion
- 2017-10-17
- Completion
- 2017-10-17
- First posted
- 2017-04-04
- Last updated
- 2019-08-07
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03100630. Inclusion in this directory is not an endorsement.